MERKEL CELL CARCINOMA

This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…

This study tested an experimental drug called INCB099318 in 105 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited…

This study tested an experimental drug called BT-001, injected directly into tumors, either alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (like melanoma, lung, or breast cancer). The goal was to see if it was safe and could shrink tumors. The…

This study tested a new radioactive drug (225Ac-SSO110) combined with standard therapy for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the best dose. The trial was stopped early and only enrolled 2 participants, so n…

This early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …

This study tested whether combining two drugs—vidutolimod (injected into tumors) and cemiplimab (given through a vein)—could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, lung cancer, and throat cancer. The trial enrolled 77 adults and…

This study tested whether adding an experimental drug (NT-I7) to an existing immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial enrolled 31 adults whose cancers had not responded t…